CN103638008B - The application of Artoxanthochromane in treatment skin carcinoma medicine - Google Patents

The application of Artoxanthochromane in treatment skin carcinoma medicine Download PDF

Info

Publication number
CN103638008B
CN103638008B CN201310634100.5A CN201310634100A CN103638008B CN 103638008 B CN103638008 B CN 103638008B CN 201310634100 A CN201310634100 A CN 201310634100A CN 103638008 B CN103638008 B CN 103638008B
Authority
CN
China
Prior art keywords
artoxanthochromane
application
skin carcinoma
present
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310634100.5A
Other languages
Chinese (zh)
Other versions
CN103638008A (en
Inventor
吴大军
李萍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XI'AN LEKOU FUTAI BIOMEDICAL TECHNOLOGY Co.,Ltd.
Original Assignee
刘艳娇
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 刘艳娇 filed Critical 刘艳娇
Priority to CN201310634100.5A priority Critical patent/CN103638008B/en
Publication of CN103638008A publication Critical patent/CN103638008A/en
Application granted granted Critical
Publication of CN103638008B publication Critical patent/CN103638008B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses the application of Artoxanthochromane in preparation treatment skin carcinoma medicine, belong to technical field of new application of medicine.The present invention is found by external MTT antineoplastic activity evaluation, and Artoxanthochromane also has significant inhibitory action to the growth of application on human skin JEG-3 A431, HME1, A375 and SK23.Therefore, Artoxanthochromane for the preparation of anti-skin carcinoma medicine, can have good development prospect.The purposes of the Artoxanthochromane that the present invention relates in preparation treatment skin carcinoma medicine is belonged to first public, and its inhibit activities for skin cancer cell is strong, has significant progress.

Description

The application of Artoxanthochromane in treatment skin carcinoma medicine
Technical field
The present invention relates to the novelty teabag of compd A rtoxanthochromane, particularly relate to the application of Artoxanthochromane in preparation treatment skin carcinoma medicine.
Background technology
Cancer is to one of maximum disease of human life's health hazard, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.74% is had to be natural product or derivatives thereof in antitumor drug, if paclitaxel and derivant thereof are exactly the current reasonable antitumor drug of effect clinically.Therefore, from natural product, anticancer compound is found or lead compound has great importance.
The compd A rtoxanthochromane that the present invention relates to is one and delivers (Horng-Huey Ko in 2013, et al., A Novel MonoterpeneStilbene Adduct with a4, 4-Dimethyl-2, 3-diphenylchromaneSkeleton from Artocarpus xanthocarpus.chemistry & biodiversity, 2013 (10): 1269-1275.) noval chemical compound, this compound has brand-new framework types, this compound energy scavenging activated oxygen (Horng-Huey Ko, et al., A Novel MonoterpeneStilbene Adduct with a4, 4-Dimethyl-2, 3-diphenylchromane Skeleton from Artocarpus xanthocarpus.chemistry & biodiversity, 2013 (10): 1269-1275.), the purposes of the Artoxanthochromane that the present invention relates in preparation treatment skin carcinoma medicine belongs to first public.
Summary of the invention
The object of the invention is to not find that it has the present situation of the report of anti-skin carcinoma activity according in existing Artoxanthochromane research, provide the application of Artoxanthochromane in the anti-skin carcinoma medicine of preparation.
Described compd A rtoxanthochromane, structure is as shown in formula I:
Formula I
The present invention is found by external MTT antineoplastic activity evaluation, Artoxanthochromane also has significant inhibitory action to the growth of application on human skin JEG-3 A431, HME1, A375 and SK23, suppresses the IC50 value of this 4 strain Growth of Cells to be respectively 2.47 ± 0.45 μMs, 1.96 ± 0.26 μMs, 1.37 ± 0.22 μMs and 1.27 ± 0.85 μMs.Therefore, Artoxanthochromane for the preparation of anti-skin carcinoma medicine, can have good development prospect.
The purposes of the Artoxanthochromane that the present invention relates in preparation treatment skin carcinoma medicine is belonged to first public, because framework types belongs to brand-new framework types, and its inhibit activities for skin cancer cell is strong, possess outstanding substantive distinguishing features, the control simultaneously for skin carcinoma obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
The preparation method of compd A rtoxanthochromane involved in the present invention is see document (Horng-Huey Ko, etal., A Novel MonoterpeneStilbene Adduct with a4,4-Dimethyl-2,3-diphenylchromaneSkeleton from Artocarpus xanthocarpus.chemistry & biodiversity, 2013 (10): 1269-1275.), compd A rtoxanthochromane is prepared according to the method described above.
Embodiment 1: the preparation of compd A rtoxanthochromane tablet involved in the present invention:
Get 5 g of compound Artoxanthochromane, add 195 grams, dextrin, mixing, Conventional compression makes 1000.
Embodiment 2: the preparation of compd A rtoxanthochromane capsule involved in the present invention:
Get 5 g of compound Artoxanthochromane, add starch 195 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Artoxanthochromane to the growth inhibited effect of application on human skin JEG-3
1. method: the cell being in growth logarithmic (log) phase: application on human skin JEG-3 A431, HME1, A375 and SK23(buy from Chinese Academy of Sciences's cell bank) with 1.5 × 10 4concentration kind is in 96 orifice plates.Original culture medium is sucked after cell culture 24h is adherent.Test is divided into blank group, drug treating group.Blank group changes 1640 culture medium containing 10% hyclone; It is 100 μMs that drug treating group is changed containing concentration, 50 μMs, 10 μMs, 1 μM, 0.1 μM, the culture medium of the Artoxanthochromane of 0.01 μM and 0.001 μM.After cultivating 48h, add the MTT of concentration 5mg/mL, continue to be put in CO 2incubator cultivates 4h, then 100 μ L supernatants are sucked along culture fluid top, add 100 μ L DMSO, 10min is placed in dark place, microplate reader (Sunrise Products) is utilized to measure light absorption value (wavelength 570nm), and calculating cell survival according to light absorption value, 6 repeating holes are established in each process.Cell survival rate (%)=Δ OD drug treating/Δ OD blank × 100.
2. the growth of result: Artoxanthochromane to application on human skin JEG-3 A431, HME1, A375 and SK23 has significant inhibitory action.This compound suppresses application on human skin JEG-3 A431, the IC50 value of HME1, A375 and SK23 growth is respectively 2.47 ± 0.45 μMs, 1.96 ± 0.26 μMs, 1.37 ± 0.22 μMs and 1.27 ± 0.85 μMs.
Shown by above-described embodiment, the growth of Artoxanthochromane of the present invention to application on human skin JEG-3 A431, HME1, A375 and SK23 has good inhibitory action.Prove thus, it is active that Artoxanthochromane of the present invention has anti-skin carcinoma, can for the preparation of anti-skin carcinoma medicine.

Claims (1)

  1. The application of 1.Artoxanthochromane in preparation treatment skin carcinoma medicine, described compd A rtoxanthochromane structure is as shown in formula I:
CN201310634100.5A 2013-12-02 2013-12-02 The application of Artoxanthochromane in treatment skin carcinoma medicine Active CN103638008B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310634100.5A CN103638008B (en) 2013-12-02 2013-12-02 The application of Artoxanthochromane in treatment skin carcinoma medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310634100.5A CN103638008B (en) 2013-12-02 2013-12-02 The application of Artoxanthochromane in treatment skin carcinoma medicine

Publications (2)

Publication Number Publication Date
CN103638008A CN103638008A (en) 2014-03-19
CN103638008B true CN103638008B (en) 2015-09-16

Family

ID=50243384

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310634100.5A Active CN103638008B (en) 2013-12-02 2013-12-02 The application of Artoxanthochromane in treatment skin carcinoma medicine

Country Status (1)

Country Link
CN (1) CN103638008B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643407T3 (en) 2014-02-07 2017-11-22 Novogen Ltd. Functionalized benzopyran compounds and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Horng-Huey Ko等.a novel monoterpene-stilbene adduct with a 4,4-dimethyl-2,3-diphenylchromane skeleton from artocarpus xanthocarpus.《Chemistry Biodiversity》.2013,第10卷(第7期),1269-1275. *
自由基生物抗氧化与疾病;崔剑 等;《清华大学学报 自然科学版》;20001231;第40卷(第6期);9-12 *

Also Published As

Publication number Publication date
CN103638008A (en) 2014-03-19

Similar Documents

Publication Publication Date Title
CN103638008B (en) The application of Artoxanthochromane in treatment skin carcinoma medicine
CN102872086B (en) The application of Houttuynoid A in treatment skin carcinoma medicine
CN103536598B (en) A kind of compound is preparing the application in Hepatoma therapy medicine
CN103463046B (en) The application of Lycojaponicumin A in preparation treatment colorectal cancer medicine
CN103446088B (en) The application of Incarviatone A in preparation treatment skin carcinoma medicine
CN103446128B (en) The application of Lycojaponicumin B in preparation treatment skin carcinoma medicine
CN103520178B (en) The application of a kind of compound in preparation treatment ovarian cancer
CN103520175B (en) The application of a kind of compound in preparation treatment cervical cancer medicine
CN103463044B (en) The application of Lycojaponicumin A in preparation treatment skin carcinoma medicine
CN103446141B (en) The application of Lycojaponicumin C in preparation treatment tongue cancer drug
CN103446086B (en) The application of Incarviatone A in preparation treatment gastric cancer medicament
CN103446133B (en) The application of Lycojaponicumin B in preparation treatment tongue cancer drug
CN103446143B (en) The application of Lycojaponicumin C in preparation treatment gastric cancer medicament
CN103463069B (en) The application of Lycojaponicumin C in preparation treatment medicine for nasopharyngeal
CN103446122B (en) The application of Lycojaponicumin B in preparation treatment carcinoma of prostate medicine
CN103405444B (en) The application of Chukrasone A in preparation treatment bladder cancer medicine
CN103494812B (en) The application of Lycojaponicumin A in preparation treatment ovarian cancer
CN103463034B (en) The application of Lycojaponicumin B in preparation treatment ovarian cancer
CN103463072B (en) The application of Lycojaponicumin C in preparation treatment bladder cancer medicine
CN103479630B (en) The application of Lycojaponicumin A in preparation treatment breast cancer medicines
CN103405406B (en) The application of a kind of compound in preparation treatment endometrial cancer drug
CN103463049B (en) The application of Lycojaponicumin B in preparation treatment breast cancer medicines
CN103463054B (en) The application of Lycojaponicumin A in preparation treatment bladder cancer medicine
CN103463033B (en) The application of Lycojaponicumin B in preparation treatment gastric cancer medicament
CN103446091B (en) The application of Incarviatone A in preparation treatment laryngeal carcinoma medicine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NANJING ZHENGLIANG PHARMACEUTICAL TECHNOLOGY CO.,

Free format text: FORMER OWNER: CHANGZHOU COLLECTION MEDICAL INSTRUMENT CO., LTD.

Effective date: 20150420

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 213000 CHANGZHOU, JIANGSU PROVINCE TO: 211200 NANJING, JIANGSU PROVINCE

TA01 Transfer of patent application right

Effective date of registration: 20150420

Address after: Qingfeng Village Yong Yang town of Lishui County of Nanjing City, Jiangsu province 211200 Green Village building 301 room 22

Applicant after: Nanjing Zhengliang Medical Technology Co.,Ltd.

Address before: 213000 West -256-1, building 4, West Taihu international wisdom garden, Wujin Economic Development Zone, Jiangsu, Changzhou

Applicant before: CHANGZHOU KELIXIN MEDICAL DEVICES CO., LTD.

ASS Succession or assignment of patent right

Owner name: LIU YANJIAO

Free format text: FORMER OWNER: NANJING ZHENGLIANG PHARMACEUTICAL TECHNOLOGY CO., LTD.

Effective date: 20150814

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent for invention or patent application
CB03 Change of inventor or designer information

Inventor after: Wu Dajun

Inventor after: Li Ping

Inventor before: Chen Jun

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: CHEN JUN TO: WU DAJUN LI PING

TA01 Transfer of patent application right

Effective date of registration: 20150814

Address after: 235000 Anhui Province, Huaibei City Xiangshan District Anhui Hengyuan coal Limited by Share Ltd dormitory

Applicant after: Liu Yanjiao

Address before: Qingfeng Village Yong Yang town of Lishui County of Nanjing City, Jiangsu province 211200 Green Village building 301 room 22

Applicant before: Nanjing Zhengliang Medical Technology Co.,Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: 225300 Jiangsu province Taizhou Gaogang Xu Zhuang Street Minghe Village No. 53

Patentee after: Liu Yanjiao

Address before: 235000 Anhui Province, Huaibei City Xiangshan District Anhui Hengyuan coal Limited by Share Ltd dormitory

Patentee before: Liu Yanjiao

C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: 235000 Anhui Province, Huaibei City Xiangshan District Anhui Hengyuan coal Limited by Share Ltd dormitory

Patentee after: Liu Yanjiao

Address before: 225300 Jiangsu province Taizhou Gaogang Xu Zhuang Street Minghe Village No. 53

Patentee before: Liu Yanjiao

C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: 234000 Xichang road in Anhui province Suzhou City Yongqiao District garden building 204 room 13 Lin Hua

Patentee after: Liu Yanjiao

Address before: 235000 Anhui Province, Huaibei City Xiangshan District Anhui Hengyuan coal Limited by Share Ltd dormitory

Patentee before: Liu Yanjiao

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20171226

Address after: 400147 Chongqing city Yubei District Longxi street new irrigation Road No. 18 building 11 Ambassador city 24-11

Patentee after: Chongqing view Intellectual Property Service Co., Ltd.

Address before: 234000 Xichang road in Anhui province Suzhou City Yongqiao District garden building 204 room 13 Lin Hua

Patentee before: Liu Yanjiao

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190301

Address after: 401120 Chongqing Yubei District Longxi Street Jinlong Road 259 Finance and Information City International 4 1-6

Patentee after: Chongqing Haoting Zhongtuo Environmental Technology Co., Ltd.

Address before: 400147 Guobin Town, 18 Xinji Avenue, Longxi Street, Yubei District, Chongqing City, 11 blocks, 24-11

Patentee before: Chongqing view Intellectual Property Service Co., Ltd.

TR01 Transfer of patent right

Effective date of registration: 20200417

Address after: No. 31001, 10 / F, unit 3, building 7, Ziming community, Changle East Road, Xincheng District, Xi'an City, Shaanxi Province

Patentee after: XI'AN LEKOU FUTAI BIOMEDICAL TECHNOLOGY Co.,Ltd.

Address before: 401120 Chongqing Yubei District Longxi Street Jinlong Road 259 Finance and Information City International 4 1-6

Patentee before: Chongqing Haoting Zhongtuo Environmental Technology Co., Ltd.

TR01 Transfer of patent right